DOI QR코드

DOI QR Code

The GSTT1 Null Genotype Contributes to Increased Risk of Prostate Cancer in Asians: a Meta-analysis

  • Pan, Zhao-Jun (Department of Urology, The Third Affiliated Hospital of Guangzhou Medical University) ;
  • Huang, Wei-Jia (Department of Urology, The Third Affiliated Hospital of Guangzhou Medical University) ;
  • Zou, Zi-Hao (Department of Urology, The Third Affiliated Hospital of Guangzhou Medical University) ;
  • Gao, Xing-Cheng (Department of Urology, The Third Affiliated Hospital of Guangzhou Medical University)
  • Published : 2012.06.30

Abstract

Background: Many studies have investigated the association between glutathione S-transferase T 1 (GSTT1) null genotype and risk of prostate cancer, but the impact of GSTT1 null genotype in Asians is still unclear owing to inconsistencies across results. Thie present meta-analysis aimed to quantify the strength of the association between GSTT1 null genotype and risk of prostate cancer. Methods: We searched the PubMed, Embase and Wangfang databases for studies of associations between the GSTT1 null genotype and risk of prostate cancer in Asians and estimated summary odds ratio (OR) with their 95% confidence interval (95% CI). Results: A total of 11 case-control studies with 3,118 subjects were included in this meta-analysis, which showed the GSTT1 null genotype to be significantly associated with increased risk of prostate cancer in Asians (random-effects OR = 1.49, 95% CI 1.15-1.92, P = 0.002), also after adjustment for heterogeneity (fixed-effects OR = 1.45, 95% CI 1.23-1.70, P < 0.001). No evidence of publication bias was observed. Conclusions: This meta-analysis of available data suggested the GSTT1 null genotype does contribute to increased risk of prostate cancer in Asians.

Keywords

Prostate cancer;GSTT1;meta-analysis;polymorphism

References

  1. Ashtiani ZO, Hasheminasab SM, Ayati M, et al (2011). Are GSTM1, GSTT1 and CAG repeat length of androgen receptor gene polymorphisms associated with risk of prostate cancer in Iranian patients? Pathol Oncol Res, 17, 269-75. https://doi.org/10.1007/s12253-010-9309-z
  2. Attia J, Thakkinstian A, D'Este C (2003). Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol, 56, 297-303. https://doi.org/10.1016/S0895-4356(03)00011-8
  3. Cochran WG (1954). The combination of estimates from different experiments. Biometrics, 10, 101-29. https://doi.org/10.2307/3001666
  4. Damber JE, Aus G (2008). Prostate cancer. Lancet, 371, 1710-21. https://doi.org/10.1016/S0140-6736(08)60729-1
  5. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  6. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  7. Foulkes WD (2008). Inherited susceptibility to common cancers. N Engl J Med, 359, 2143-53. https://doi.org/10.1056/NEJMra0802968
  8. Galbraith RF (1988). A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med, 7, 889-94. https://doi.org/10.1002/sim.4780070807
  9. Guyatt G, Oxman AD, Akl EA, et al (2011). GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol, 64, 383-94. https://doi.org/10.1016/j.jclinepi.2010.04.026
  10. Hayes JD, Flanagan JU, Jowsey IR (2005). Glutathione transferases. Annu Rev Pharmacol Toxicol, 45, 51-88. https://doi.org/10.1146/annurev.pharmtox.45.120403.095857
  11. Hayes JD, Strange RC (2000). Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology, 61, 154-66. https://doi.org/10.1159/000028396
  12. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60. https://doi.org/10.1136/bmj.327.7414.557
  13. Hoffman RM (2011). Clinical practice. Screening for prostate cancer. N Engl J Med, 365, 2013-9. https://doi.org/10.1056/NEJMcp1103642
  14. Ioannidis JP, Patsopoulos NA, Evangelou E (2007). Uncertainty in heterogeneity estimates in meta-analyses. BMJ, 335, 914-6. https://doi.org/10.1136/bmj.39343.408449.80
  15. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  16. Komiya Y, Tsukino H, Nakao H, et al (2005). Human glutathione S-transferase A1, T1, M1, and P1 polymorphisms and susceptibility to prostate cancer in the Japanese population. J Cancer Res Clin Oncol, 131, 238-42. https://doi.org/10.1007/s00432-004-0634-z
  17. Kumar V, Yadav CS, Datta SK, et al (2011). Association of GSTM1 and GSTT1 polymorphism with lipid peroxidation in benign prostate hyperplasia and prostate cancer: a pilot study. Dis Markers, 30, 163-9. https://doi.org/10.1155/2011/624961
  18. Kwon DD, Lee JW, Han DY, et al (2011). Relationship between the Glutathione-S-Transferase P1, M1, and T1 Genotypes and Prostate Cancer Risk in Korean Subjects. Korean J Urol, 52, 247-52. https://doi.org/10.4111/kju.2011.52.4.247
  19. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  20. Mittal RD, Mishra DK, Mandhani A (2006). Evaluating polymorphic status of glutathione-S-transferase genes in blood and tissue samples of prostate cancer patients. Asian Pac J Cancer Prev, 7, 444-6.
  21. Mittal RD, Srivastava DS, Mandhani A, et al (2004). Polymorphism of GSTM1 and GSTT1 genes in prostate cancer: a study from North India. Indian J Cancer, 41, 115-9.
  22. Murata M, Watanabe M, Yamanaka M, et al (2001). Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population. Cancer Lett, 165, 171-7. https://doi.org/10.1016/S0304-3835(01)00398-6
  23. Nakazato H, Suzuki K, Matsui H, et al (2003). Association of genetic polymorphisms of glutathione-S-transferase genes (GSTM1, GSTT1 and GSTP1) with familial prostate cancer risk in a Japanese population. Anticancer Res, 23, 2897-902.
  24. Petitti DB. (2000) Meta-analysis, decision analysis, and cost effectiveness analysis: methods for quantitative synthesis in medicine(2nded). New York, NY: Oxford University Press.
  25. Srivastava DS, Mandhani A, Mittal B, et al (2005). Genetic polymorphism of glutathione S-transferase genes (GSTM1, GSTT1 and GSTP1) and susceptibility to prostate cancer in Northern India. BJU Int, 95, 170-3. https://doi.org/10.1111/j.1464-410X.2005.05271.x
  26. Stuck AE, Rubenstein LZ, Wieland D (1998). Bias in metaanalysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ, 316, 469. https://doi.org/10.1136/bmj.316.7129.469
  27. Thakur H, Gupta L, Sobti RC, et al (2011). Association of GSTM1T1 genes with COPD and prostate cancer in north Indian population. Mol Biol Rep, 38, 1733-9. https://doi.org/10.1007/s11033-010-0287-8
  28. Tobias A (1999). Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull, 8, 15-7.
  29. Yang J, Wu HF, Zhang W, et al (2006). Polymorphisms of metabolic enzyme genes, living habits and prostate cancer susceptibility. Front Biosci, 11, 2052-60.

Cited by

  1. Korean Prostate Cancer Patients Have Worse Disease Characteristics than their American Counterparts vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6913
  2. Toxicogenetic Profile and Cancer Risk in Lebanese vol.17, pp.2, 2014, https://doi.org/10.1080/10937404.2013.878679